Platform-Agnostic SNP Genotyping and Allele-Specific PCR with PACE Master Mixes

PACE® – Your Universal Solution!

In the rapidly evolving world of genomic research and breeding, having versatile reagents that can seamlessly adapt to different platforms is paramount. Enter PACE® – for platform-agnostic SNP genotyping by the power of allele-specific PCR. This innovative solution is changing the game, offering researchers and breeders a universal toolkit for precision genotyping with unparalleled flexibility and reliability.

Unlocking Genetic Insights with SNP Genotyping and Allele-Specific PCR

SNP genotyping and allele-specific PCR are cornerstones of modern genetic analysis, allowing scientists to track and monitor genetic variations with pinpoint accuracy. With PACE genotyping reagents, you can reach new heights of efficient and accuracy at market-leading prices.

Precision Across Platforms: PACE Genotyping Master Mixes

PACE genotyping master mixes are platform agnostic for precision PCR genotyping. PACE’s patented genotyping chemistry has been meticulously designed to perform across all PCR genotyping platforms and reaction volumes, providing consistently accurate results. In addition, all our PACE genotyping mixes are supplied with Standard, High, Low, or No ROX normalisation dye options for optimal performance.

Join the PACE Revolution

Join the ranks of researchers and breeders who have found affordable precision, flexibility, and reliability with PACE genotyping reagents. PACE genotyping master mixes are compatible with all major PCR genotyping platforms, including 96-, 384-, and 1536- well PCR plates, and Array Tape®. PACE generates accurate data regardless of the reaction volume; PACE Genotyping master mixes are also suitable for BiomarkX and BiomarkHD automated, chip-based PCR systems from Standard Biotools (formerly Fluidigm) that use microfluidics technology to process samples at nanoliter-scale volumes.

Spotlight on Microfluidics: Scaling Up with PACE and Biomark™ X9

By harnessing the power of microfluidics technology, PACE enables high-throughput, scalable SNP and Indel marker development and screening. This makes it an ideal solution for large-scale, cost-effective allele-specific PCR analysis and SNP genotyping using microfluidics platforms such as the Biomark X9 System from Standard Biotools. The Biomark platforms offer automated, high-performance PCR at nanolitre volumes and simultaneous monitoring of markers across numerous samples, drastically reducing both time and cost.

Breeders and researcher alike can develop platform-agnostic SNP marker sets on these and similar high-throughput platforms, utilising PACE genotyping reagents for universal reporting. PACE is compatible with multiple other throughput platforms downstream to ensure future-proof automation, and reproducibility.

Read Our New Application Note

Check out our latest app note in collaboration with Standard Biotools, showcasing the exemplary performance of our PACE chemistry on the Biomark X9 System with compelling use case study and data. We included typical data from a prominent public research institute analysing 96 samples across 96 SNPs, revealing remarkable results of tight clustering and high concordance of SNPs. This representative data underscores the accuracy and reliability of our technology even at nanoliter-scale volumes, affirming its utility in diverse research settings. Explore the full app note to delve deeper into the implications of this technology partnership and discover how our innovate solutions can advance your research endeavours.

Next-generation sequencing (NGS) for SNP discovery followed by PACE SNP marker saturation in quantitative trait loci (QTL) intervals is a great, real-world example of the utility of this combination. Designing PACE genotyping assays against SNP variants, high-throughput screening using the Biomark X9 System, and genotyping recombinants on lower-throughput platforms demonstrates the versatility in research and breeding applications.

Figure 1. Example data of 96 samples over 96 SNPs. Data calling (A) from the heat map (B) shows tight clustering and a high concordance of SNPs in the principal component analysis plot. Actual data from a high-throughput genotyping and sequencing technology service provider for a public research institute using PACE genotyping with the Biomark X9.

Conclusion: PACE – Redefining Genomic Research and Breeding

In conclusion, PACE genotyping master mixes are a game-changer in the world of genomic research and breeding. PACE’s patented, platform-agnostic design, compatibility with high-throughput systems like the BiomarkX9 System from Standard Biotools, and unparalleled performance make it the go-to solution for researchers and breeders looking to unlock the full potential of their genotyping assays.

Biomark X9 System: Scalable SNP and indel marker development
This field is for validation purposes and should be left unchanged.

Contact us


Steve Asquith Managing Director
Steve began his career in the Genetics Division of GlaxoSmithKline, as part of the team establishing GSK’s high-throughput core genotyping laboratory. Steve joined KBioscience when it was first founded in 2002 and was a key driver in taking the company from a small start-up to a multi-national service laboratory, quickly growing the company’s revenue to over $7.5M p.a. Following the acquisition of Kbioscience by LGC in 2011, Steve was appointed Global Director of Operations for LGC Genomics, responsible for over 100 staff in Europe and N. America, successfully elevating the genotyping products and service business. Steve held a crucial leadership role until he left in 2016. In 2017 Steve joined forces with John Holme to create 3CR Bioscience, a new company with a mission to deliver outstanding, customer-focused genotyping products with innovation and affordability at its core.
Dr. John Holme Technical Director
John joined KBioscience shortly after it was founded, in 2003, and became Head of Technical Development, building the company’s genotyping and DNA extraction product portfolio and service delivery until 2011 when it was acquired by LGC. Post-acquisition, John was appointed Head of Technical Group for LGC Genomics, in charge of all Research & Development and Technical Support activities for the company. In this role John continued to build on the high-quality products and services provided to the companies growing customer base. During the 19 years John has worked in commercial R&D, he has co-invented numerous highly successful products including PACE®, ProbeSure, KASP™, KlearKall, KlearGene, KlearAmp and KlearTaq™, creating breakthrough offerings in genotyping and extraction and generating huge revenues for the companies he has worked in. In 2017, he joined forces with Steve Asquith and started 3CR Bioscience. John is dedicated to developing outstanding, innovative genotyping products and providing the very best technical support to customers globally.
Dr. Nisha JainOperations Director
Nisha has been innovating since the start of her career at Geneform Technologies developing Iso-thermal Genotyping Technologies. Nisha joined KBioscience in 2008, as Senior R&D Scientist and key account Technical Support Scientist, developing KASP and Klearkall performance and coinventing two further versions of KASP. Nisha has more than 15 years’ experience working in molecular biology and genotyping technologies, with extensive experience in the areas of R&D, Quality Assurance and Customer Technical Support. She has technically assisted many giants of the industry with their protocol development and troubleshooting and continues to deliver high-quality support and guidance. In 2018, Nisha joined 3CR Bioscience as Operations Director where she continues to develop PACE and ProbeSure for an increasing range of applications, and to grow 3CR Bioscience’s new product pipeline. Nisha is dedicated to developing outstanding, innovative genotyping products and providing the very best technical support to customers globally.
Nazma Saffin General Manager
For 20 years Nazma Saffin has worked and gained extensive expertise within the genotyping sector. Working at Kbioscience and then LGC, she has held operational leadership posts responsible for manufacturing and laboratory services. With experience of ISO 9001 implementation, production scale up and LEAN operations, Nazma has successfully led highly profitable production departments. Joining 3CR Bioscience in 2022, Nazma is committed to delivering operational excellence.
Jon Curtis Non-Executive Chair
After 8 years in The Royal Air Force, Jon moved to the Imperial Cancer Research Fund where he pioneered the use of ultra high-throughput genomic automation, capable of 46,000 PCRs per hour. In the 1990’s Jon joined GlaxoSmithKline, implementing a high-throughput genomics platform into their drug discovery pipeline. Whilst there he also developed acoustic mixing into compound management, becoming the gold standard across pharma. Jon developed the world’s first commercially viable 1536-well PCR plates, automated thermal & laser plate-sealer, plus automated liquid-handling & tip washing tools to reduce waste and costs. In 2002 Jon co-founded KBioscience with Phil Robinson, utilising ultra high-throughput PCR instrumentation & a suite of automation tools to create the company’s SNPline robotic platform, with a capacity of 250,000 PCRs/day. The business was underpinned by their ground-breaking patented genotyping chemistry, KASP™, which has over 10,000 scientific papers to date. In November 2022 Jon joined 3CR Bioscience acting as an advisor bringing his commercial and scientific experience to the company.